Differential effects of carvedilol and metoprolol on renal function in patients with heart failure

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1578-1583

  Ito, Hiroyuki ^a   Nagatomo, Yuji ^a   Kohno, Takashi ^a   Anzai, Toshihisa ^a   Meguro, Tomomi ^a   Ogawa, Satoshi ^a   Yoshikawa, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

blocker; Carvedilol; Glomerular filtration rate; Heart failure; Metoprolol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARVEDILOL TARTRATE; LIPID PEROXIDE; METOPROLOL TARTRATE; NORADRENALIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG PREFERENCE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY FUNCTION; MALE; NORADRENALIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; TREATMENT DURATION;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; CARBAZOLES; DRUG EVALUATION; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; METOPROLOL; MIDDLE AGED; PROPANOLAMINES; RETROSPECTIVE STUDIES; STROKE VOLUME;

EID: 77955081311     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0865     Document Type: Article

References (25)

1. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004; 44: 959-966.
2. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insuf-fciency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009.
3. Tamura A, Kawano Y, Kadota J. Carvedilol reduces the severity of central sleep apnea in chronic heart failure. Circ J 2009; 73: 295-298.
4. Kataoka M, Satoh T, Yoshikawa T, Nakamura I, Kohno T, Yoshizawa A, et al. Comparison of the effects of carvedilol and metoprolol on exercise ventilatory effciency in patients with congestive heart failure. Circ J 2008; 72: 358-363.
5. Yamaji M, Tsutamoto T, Tanaka T, Kawahara C, Nishiyama K, Yamamoto T, et al. Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J 2009; 73: 1067-1073.
6. Dreslinski GR, Messerli FH, Dunn FG, Suarez DH, Reisin E, Frohlich ED. Hemodynamics, biochemical and refexive changes produced by atenolol in hypertension. Circulation 1982; 65: 1365-1368.
7. Sugino G, Barg AP, O'Connor DT. Renal perfusion is preserved during cardioselective beta-blockade with metoprolol in hypertension. Am J Kidney Dis 1984; 3: 357-361.
8. Epstein M, Oster JR. β-blockers and renal function: A reappraisal. J Clin Hypertens 1985; 1: 85-99.
9. Dupont AG, Van der Niepen P, Taeymans Y, Ingeis M, Piepsz A, Bossuyt AM, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10(Suppl 11): S130-S136.
10. Tomita K, Makumo F. Effect of long-term carvedilol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992; 19(Suppl 1): S97-S101.
11. Yokota Y, Nomura H, Kawai H, Tsumura Y, Takeuchi Y, Kurozumi H, et al. Effects of long-term beta-blockade (metoprolol) therapy in patients with dilated cardiomyopathy. Jpn Circ J 1991; 55: 343-355.
12. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The multicenter carvedilol heart failure dose assessment (MUCHA) trial. Am Heart J 2004; 147: 324-330.
13. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Estimation of glomerular fltration rate by the MDRD study equation modifed for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
14. Kovalova S, Necas J, Cerbak R, Malik P, Vespalec J. Echocardio-graphic volumetry of the right ventricle. Eur J Echocardiogr 2005; 6: 15-23.
15. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Defnition and Classifcation of Cardiomyopathies. Circulation 1996; 93: 841-842.
16. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insuffciency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44: 1587-1592.
17. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41: 1438-1444.
18. Yoshizawa A, Yoshikawa T, Nakamura I, Satoh T, Moritani K, Suzuki M, et al. Brain natriuretic peptide response is heterogeneous during β-blocker therapy for congestive heart failure. J Card Fail 2004; 10: 310-315.
19. Kohno T, Yoshikawa T, Yoshizawa A, Nakamura I, Anzai T, Satoh T, et al. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. Cardiovasc Drugs Ther 2005; 19: 349-355.
20. Leeman M, Verrerstraeten P, Uytdenhoef M, Degaute JP. Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients. J Cardiovasc Pharmacol 1993; 22: 706-710.
21. Ghali JK, Wikstrand J, Van Veldhuisen DJ, Fagerberg B, Goldstein S, Hjalmarson A, et al. The infuence of renal function on clinical outcome and response to β-blockade in systolic heart failure: Insights from metoprolol CR/XL randomized intervention trial in chronic HF (MERIT-HF). J Card Fail 2009; 15: 310-318.
22. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 2004; 292: 2227-2236.
23. Gilner V, Tormos C, Chaves FJ, Sáez G, Redón J. Microalbuminuria and oxidative stress in essential hypertension. J Intern Med 2004; 255: 588-594.
24. Singh D, Chander V, Chopra K. Carvedilol attenuates ischemia-reperfusion-induced renal injury in rats. Fundam Clin Pharmacol 2004; 18: 627-634.
25. Wong VY, Laping NJ, Nelson AH, Contino LC, Olson BA, Gygielko E, et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGFβ expression. Br J Pharmacol 2001; 134: 977-984.